An observational study in Diffuse Large B-cell Lymphoma, sponsored by Incyte Corporation. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Incyte Corporation · Observational
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
This observational study is intended to further characterize the safety and effectiveness of tafasitamab, in combination with lenalidomide, in patients with R/R DLBCL in the US, with a focus on racial and ethnic minorities.
This study also characterizes the overall treatment patterns (e.g., line of treatment, dose modification, combination partners, use as monotherapy) of US patients with R/R DLBCL who have been treated with tafasitamab with a focus on racial and ethnic minorities This multicenter real-world study will help to characterize the use of tafasitamab (e.g., line of treatment, dose modification, combination partners, use as monotherapy) among US patients with R/R DLBCL with a focus on racial and ethnic minorities This is an observational study; as such, no study visits or assessments, laboratory tests or procedures are mandated by the study. Patients will be evaluated and treated according to the physician's usual practice and discretion.
Patient data for this observational study will be collected in one of two ways; either
1,390 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 350 are open to participants now.
This study's enrollment of 102 is below the median of 153 across 150 observational studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Incyte Corporation is the lead sponsor of 286 studies on the registry; 37 are open to participants now.
Of its 144 completed or terminated interventional studies of FDA-regulated products, 93 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Community Study- 40 sites across the USA
Criteria: Inclusion Criteria:
Histologically confirmed DLBCL such as:
a) DLBCL not otherwise specified (NOS) b) T-cell histiocyte-rich large B-cell lymphoma (THRLBCL) c) Epstein-Barr virus (EBV)-positive DLBCL of the elderly d) Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse, according to Revised European American Lymphoma (REAL)/World Health Organization (WHO) classification e) Patients with evidence of histological transformation to DLBCL from an earlier diagnosis of low-grade lymphoma (i.e., an indolent pathology such as follicular lymphoma [FL], marginal zone lymphoma [MZL], chronic lymphocytic leukemia [CLL]) with a subsequent DLBCL relapse f) High-grade B-cell lymphoma: i) DLBCL with MYC and BCL2 or BCL6 translocation (double-hit) and MYC and BCL2 and BCL6 translocations (triple-hit) ii) High-grade B-cell lymphoma, NOS
Exclusion Criteria:
Group 1: Racial and ethnic minority patients (at least 50 patients)
Drug: Tafasitamab
Group 2: Non Hispanic White (NHM) patients (at least 50 patients)
Drug: Tafasitamab
Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
Treatment Patterns - Safety
Incidence and severity of Treatment-emergent serious AEs (SAEs) and AEs (TEAs)
Time frame: 2 Years
Treatment Patterns - Effectiveness (a)
Objective response rate (ORR)
Time frame: 2 Years
Treatment Patterns - Effectiveness (b)
Complete response (CR) rate
Time frame: 2 Years
Treatment Patterns - Effectiveness (c)
Duration of response (DoR)
Time frame: 2 Years
Treatment Patterns - Effectiveness (d)
OS
Time frame: 2 Years
Treatment Patterns - Effectiveness (e)
Progression-free survival (PFS)
Time frame: 2 Years
Treatment Patterns - Effectiveness (f)
Event-free survival (EFS)
Time frame: 2 Years
Physician-reported clinical outcome (a)
Number of treatment lines prior to receiving tafasitamab
Time frame: 2 Years
Physician-reported clinical outcome (b)
Distribution of treatment regimens by lines of therapy prior to and subsequent to tafasitamab treatment Duration of tafasitamab treatment (regardless of concomitant treatment with lenalidomide)
Time frame: 2 Years
Physician-reported clinical outcome (c)
Duration of combination treatment (i.e., duration of treatment with both tafasitamab and lenalidomide)
Time frame: 2 Years
Physician-reported clinical outcome (d)
Modifications of dose and treatment schedule of tafasitamab and/or lenalidomide
Time frame: 2 Years
Physician-reported clinical outcome (e)
Incidence of tafasitamab use with combination partners other than lenalidomide
Time frame: 2 Years
Physician-reported clinical outcome (f)
Incidence of tafasitamab use as monotherapy (i.e., without any combination partners)
Time frame: 2 Years
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse→
Incyte Corporation